Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
Advertisement

Related Content

Lilly Zyprexa, Symbyax Labeling Strengthened
Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug
Atypical Antipsychotics Falter In STEP-BD Study
Zyprexa Could Gain From CATIE Cost/Benefit Analysis, Lilly Says
Lilly Funding Study Of Corcept's Corlux For Mitigation Of Zyprexa Weight Gain
Antipsychotic Drug Stabilization Period For Long-Term Studies Can Be Short, Vanda Pharma Says
Zyprexa Reduced Hospitalization Rate In CATIE Study Is Key For Payors, Lilly Says
Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
Geodon Labeling Changes Still Under Discussion, Pfizer Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel